PE20250781A1 - Composicion farmaceutica y que comprende derivados de difenildiazol metodos de uso - Google Patents

Composicion farmaceutica y que comprende derivados de difenildiazol metodos de uso

Info

Publication number
PE20250781A1
PE20250781A1 PE2024001775A PE2024001775A PE20250781A1 PE 20250781 A1 PE20250781 A1 PE 20250781A1 PE 2024001775 A PE2024001775 A PE 2024001775A PE 2024001775 A PE2024001775 A PE 2024001775A PE 20250781 A1 PE20250781 A1 PE 20250781A1
Authority
PE
Peru
Prior art keywords
diphenyldiazole
pharmaceutical composition
fatty acid
polyethylene glycol
compound
Prior art date
Application number
PE2024001775A
Other languages
English (en)
Spanish (es)
Inventor
Armin Giese
Johannes Levin
Vesco Emanuela Del
Original Assignee
Modag Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modag Gmbh filed Critical Modag Gmbh
Publication of PE20250781A1 publication Critical patent/PE20250781A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2024001775A 2022-03-01 2023-03-01 Composicion farmaceutica y que comprende derivados de difenildiazol metodos de uso PE20250781A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22159408 2022-03-01
PCT/EP2023/055160 WO2023166045A1 (en) 2022-03-01 2023-03-01 Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use

Publications (1)

Publication Number Publication Date
PE20250781A1 true PE20250781A1 (es) 2025-03-14

Family

ID=80623476

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001775A PE20250781A1 (es) 2022-03-01 2023-03-01 Composicion farmaceutica y que comprende derivados de difenildiazol metodos de uso

Country Status (12)

Country Link
US (1) US20250161273A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486340A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508912A (cg-RX-API-DMAC7.html)
KR (1) KR20240155237A (cg-RX-API-DMAC7.html)
CN (1) CN118715010A (cg-RX-API-DMAC7.html)
AU (1) AU2023227368A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246018A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002379A1 (cg-RX-API-DMAC7.html)
IL (1) IL314952A (cg-RX-API-DMAC7.html)
MX (1) MX2024009773A (cg-RX-API-DMAC7.html)
PE (1) PE20250781A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023166045A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024349468A1 (en) 2023-09-26 2026-04-16 Teva Pharmaceutical Industries Ltd. Emrusolmin for use in treating multiple system atrophy
KR20250090047A (ko) * 2023-12-12 2025-06-19 가천대학교 산학협력단 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물
WO2026139903A1 (en) 2024-12-23 2026-07-02 Teva Pharmaceutical Industries Ltd. Solid state forms of emrusolmin and process for preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2714453T3 (es) * 2008-06-09 2019-05-28 Univ Muenchen Ludwig Maximilians Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
KR102671166B1 (ko) * 2015-12-14 2024-05-31 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 3,5-디페닐-디아졸 화합물의 수용성 유도체

Also Published As

Publication number Publication date
KR20240155237A (ko) 2024-10-28
EP4486340A1 (en) 2025-01-08
AU2023227368A1 (en) 2024-07-18
CN118715010A (zh) 2024-09-27
US20250161273A1 (en) 2025-05-22
JP2025508912A (ja) 2025-04-10
IL314952A (en) 2024-10-01
WO2023166045A1 (en) 2023-09-07
CL2024002379A1 (es) 2025-01-24
CA3246018A1 (en) 2023-09-07
MX2024009773A (es) 2024-08-19

Similar Documents

Publication Publication Date Title
AR109789A2 (es) Compuestos lipídicos
CL2023003223A1 (es) Derivado de fosfonilo, y composición y aplicación farmacéutica de este
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20232051A1 (es) Compuestos carboxi-benzimidazol moduladores de glp-1r
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
PE20251600A1 (es) Compuestos que contienen heteroatomos y usos de estos
AR035498A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos, su uso en la preparacion de medicamentos, intermediarios para su preparacion y composiciones farmaceuticas que los contienen
AR070299A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas
RU2013121788A (ru) Ингибиторы репликации вич
JP2013525286A5 (cg-RX-API-DMAC7.html)
AR035612A1 (es) 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa
AR062398A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar obesidad, hirsutismo, hipertricosis y verrugas viricas
AR133241A1 (es) Compuestos, composiciones y métodos
UY39265A (es) Compuestos como activadores de cav1.2 y composiciones farmacéuticas que los contienen
AR123543A1 (es) DERIVADOS DE 2-(3-PIRIDIN-2-IL-4-QUINOLIN-4-IL-PIRAZOL-1-IL)-ACETAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b-1 / ALK5
AR127431A1 (es) Compuestos novedosos
AR133240A1 (es) Compuestos, composiciones y métodos
JP2025508912A5 (cg-RX-API-DMAC7.html)
PE20251401A1 (es) Inhibidores de topoisomerasa-1 derivados de exatecan composiciones farmaceuticas y sus usos
DOP2025000009A (es) Inhibidores de acc novedosos
AR065419A1 (es) Metodo para inhibir la proliferacion de celulas tumorales
AR130118A1 (es) Agente degradante de proteína quinasa, medicamento y uso
AR128917A1 (es) Inhibidores de malt-1 de tiazolo[5,4-b]piridina
CO2021006087A2 (es) Compuestos aromáticos y usos farmacéuticos de los mismos
RU2017137960A (ru) Применение тиаоксосоединений для уменьшения содержания аро сз